GlaxoSmithKline's new diabetes med faces formidable GLP-1 foes

There's a new kid on the diabetes block. GlaxoSmithKline's ($GSK) albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday. Now, the drug will go up against a triad of other GLP-1 treatments, including Novo Nordisk's ($NVO) powerhouse Victoza and AstraZeneca's ($AZN) exanatide franchise. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.